The serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis.
Norman Gitlin
Abstract
Norman Gitlin
Abstract
The SGOT/SGPT ratio was studied in 25 patients with severe acute viral hepatitis due to either B or non A-non B hepatitis. The transaminase levels were performed within 10 days of onset of the hepatitis or within 4 days of the diagnosis of fulminant hepatic failure. Twelve patients died of their acute illness. There was a significant difference between the SGOT/SGPT ratios of females who died mean = 2.05) and lived (mean 0.45) (p less than 0.001) and between the SGOT/SGPT ratios of males who died (mean - 1.01) and lived (mean 0.45) (p less than 0.02). Using 95% confidence intervals the expected ratios for combined sexes were calculated to be 0.31 to 0.63 for survivors and from 1.20 to 2.26 for nonsurvivors. Neither age not viral etiology affected the prognosis in this study.
OpenAlex reports 39 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The SGOT/SGPT ratio was studied in 25 patients with severe acute viral hepatitis due to either B or non A-non B hepatitis. The transaminase levels were performed within 10 days of onset of the hepatitis or within 4 days of the diagnosis of fulminant hepatic failure. Twelve patients died of their acute illness. There was a significant difference between the SGOT/SGPT ratios of females who died mean = 2.05) and lived (mean 0.45) (p less than 0.001) and between the SGOT/SGPT ratios of males who died (mean - 1.01) and lived (mean 0.45) (p less than 0.02). Using 95% confidence intervals the expected ratios for combined sexes were calculated to be 0.31 to 0.63 for survivors and from 1.20 to 2.26 for nonsurvivors. Neither age not viral etiology affected the prognosis in this study.
Key concepts: Medicine, Viral hepatitis, Fulminant hepatitis, Internal medicine, Transaminase, Gastroenterology, Fulminant, Etiology